Format

Send to

Choose Destination
Eur J Paediatr Neurol. 2019 May;23(3):347-356. doi: 10.1016/j.ejpn.2019.03.004. Epub 2019 Mar 21.

Quality of life of patients with spinal muscular atrophy: A systematic review.

Author information

1
Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address: erik.landfeldt@ki.se.
2
Saco, Stockholm, Sweden.
3
The Department of Women's and Children's Health, Paediatric Neurology, Karolinska Institutet, Karolinska University Hospital, Astrid Lindgren Children's Hospital, Stockholm, Sweden.
4
Department of Pediatrics, University of Gothenburg, Queen Silvia Children's Hospital, Gothenburg, Sweden.
5
Department of Neuropediatrics and Muscle Disorders, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany; Children's Hospital of Eastern Ontario and The Ottawa Hospital, Department of Paediatrics, Division of Neurology, University of Ottawa, Ottawa, Canada; Children's Hospital of Eastern Ontario and The Ottawa Hospital, Department of Medicine, Division of Neurology, University of Ottawa, Ottawa, Canada.
6
Department of Neuropediatrics and Muscle Disorders, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.

Abstract

OBJECTIVES:

To systematically review the literature of quality of life (QoL) of patients with spinal muscular atrophy (SMA), a rare, autosomal-recessive neuromuscular disease associated with extensive morbidity and elevated mortality.

METHODS:

We searched Embase, Web of Science, and PubMed for full-text, English-language articles (published between January 1, 2000 and July 31, 2018) reporting results from studies of QoL of patients with SMA. We excluded review and editorial articles, studies reporting results for samples comprising <5 patients (to allow for meaningful inference), and case reports/qualitative assessments.

RESULTS:

Of 824 identified articles, 15 met study criteria. Included publications contained data derived from samples from a total of 11 countries and three continents (Europe, North America, and South America). Estimates of the latent trait, primarily derived using the Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales and the PedsQL 3.0 Neuromuscular Module, indicated impairment in patient QoL, in particular physical functioning. However, both patient self- and caregiver proxy-assessments varied markedly across studies and subgroups. Among adult individuals, the mean self-assessed EuroQol-5D-3L utility has been estimated at 0.16 for a pooled sample of patients with SMA type I, II, and III, and -0.01 for SMA type II. Little is known of the impact of available treatments, including nusinersen, on patient QoL.

CONCLUSIONS:

Our review show that QoL is impaired in SMA, mainly due to compromised physical health, but also reveal that little is known of the impact of the disease across different phenotypes and clinical interventions.

KEYWORDS:

Decision making; Health policy; Neuromuscular diseases; Quality of life; SMA

PMID:
30962132
DOI:
10.1016/j.ejpn.2019.03.004

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center